Skip to main content
Equibles
TIL logo

TIL · Instil Bio, Inc. · Metrics

Track TIL — free

Use TIL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TIL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.95 -0.27 (-3.74%) At close · Oct 5
Rebalance outlook locked
Going-concern doubt — cleared Aug 13, 2026

The latest filing states the doubt was alleviated.

“As discussed above and in Note 10 to the accompanying condensed consolidated financial statements, the 2024 Loan is due in January 2027, for total principal of $85.6 million, which is in excess of cash, cash equivalents, and marketable securities on hand as of June 30, 2026, which we concluded is an indicator of substantial doubt about our ability to continue as a going concern. We concluded that management's plans, including Complex Therapeutics LLC's contractual right to exercise the extension option to January 2028, which is within Complex Therapeutics LLC's control, alleviate the conditions that raise substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$48.63M
Shares
6.78M
Volume · Oct 5 12.94K Avg daily vol (3M) 11.8K

TIL metrics

51 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.95
Market cap
$48.63M

Price action

20 metrics
Price change (1W)
+0.7%
Price change (30D)
-7.7%
Price change (3M)
-6.6%
Price change (6M)
-10.1%
Price change (YTD)
-34.4%
Price change (1Y)
-58.9%
Trailing year
Price change (5Y)
—
52-week high
$21.10
52-week low
$6.66
Change from 52-week high
-65.8%
Change from 52-week low
+8.4%
Annualized volatility
68.3%
Annualized volatility (3M)
24.5%
Beta
0.9
RSI (14D)
46.5
Price vs SMA 50
-2.0%
Price vs SMA 200
-10.1%
Avg volume (3M)
11,785
Relative volume
2.4
Average dollar volume
$86,796

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
6.78M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.5
reciprocal yield 220.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-62.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$37.17M
Net income (TTM)
−$30.28M
Trailing 12 months
Diluted EPS (TTM)
$-4.39
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$16.79

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-28.2%
Return on assets
-15.3%
Debt / equity
—
Current ratio
21.7
EBITDA (TTM)
−$36.89M
Free cash flow (TTM)
—
Quick ratio
21.7
Interest coverage
-5.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$5.54M
Total assets
$197.71M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$23.61M
Capital expenditures (TTM)
$0
R&D (TTM)
$13.56M
SG&A (TTM)
—
Stock compensation (TTM)
$5.39M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
26
13F filer change QoQ
-6
Institutional ownership
56.1%

Short interest

3 metrics
Short interest
2.4%
Latest settlement · 13.1 days to cover
Days to cover
13.1d
Short-squeeze score
58 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1789769 CUSIP 45783C200 13F (30d) 1 filings 1 filers Visit website Investor relations